<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992784</url>
  </required_header>
  <id_info>
    <org_study_id>113094</org_study_id>
    <nct_id>NCT00992784</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People</brief_title>
  <official_title>Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety of GSK Biologicals' influenza vaccine.
      Elderly subjects were randomized in the primary study (NCT00760617) and will now receive the
      same vaccine for the third time. For this study the masking is &quot;observer-blind&quot; for elderly
      subjects and &quot;open&quot; for young adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Grade 3 ecchymosis, redness and swelling was ≥ 100 millimeter (mm) and grade 3 pain was considerable pain at rest, that prevented normal everyday activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Local AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Duration was defined as number of days with any grade of local symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C-≤ 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade, grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited General AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <description>Duration was defined as number of days with any grade of general symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>Day 0-20</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit</measure>
    <time_frame>Day 0-179</time_frame>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting AEs of Specific Interest (AESI)</measure>
    <time_frame>Day 0-179</time_frame>
    <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) up to Day 180</measure>
    <time_frame>Up to Day 180</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) After Day 180</measure>
    <time_frame>After Day 180</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21</measure>
    <time_frame>Day 0 and Day 21</time_frame>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs) against separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Titers at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>Antibody titers were expressed as GMTs against separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seropositive to HI Antibodies at Days 0 and 21</measure>
    <time_frame>Day 0 and Day 21</time_frame>
    <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seropositive to HI Antibodies at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies at Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies at Day 180</measure>
    <time_frame>Day 180</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors (SCF) at Day 21</measure>
    <time_frame>At Day 21</time_frame>
    <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody SCF at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies at Days 0 and 21</measure>
    <time_frame>At Day 0 and Day 21</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ to 1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected to HI Antibodies at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strains Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21</measure>
    <time_frame>At Day 0 and Day 21</time_frame>
    <description>The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The GM Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Day 180</measure>
    <time_frame>At Day 180</time_frame>
    <description>The markers assessed were CD40L, IL-2, TNF-α and IFN-γ and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix young Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK investigational vaccine 2186877A</intervention_name>
    <description>Single dose, intramuscular injection</description>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluarixTM</intervention_name>
    <description>Single dose, intramuscular injection</description>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_label>Fluarix young Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy ALL the following criteria at study entry:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study. Specific attention
             should be given to the compliance potential of subjects with suspected drug or alcohol
             abuse.

          -  A male or female aged 19-43 years or &gt;=66 years at the time of the vaccination and who
             participated in the study NCT00760617 and completed the 6-month follow-up.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             evaluation before entering into the study.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,
             hysterectomy, ovariectomy or post-menopause.

          -  Female subjects of childbearing potential may be enrolled in the study if the subject:

          -  has practiced adequate contraception for 30 days prior to vaccination, and

          -  has a negative pregnancy test on the day of vaccination, and

          -  has agreed to continue adequate contraception for 2 months after the vaccination.

        Exclusion Criteria:

        The following criteria should be checked at the time of study entry. If ANY exclusion
        criterion applies, the subject must not be included in the study:

          -  Use of any investigational or non-registered product other than the study vaccine(s)
             within 30 days prior to vaccination, or planned use during the study period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study. Planned administration
             of an influenza vaccine other than the study vaccines or of a vaccine not foreseen in
             the study protocol during the entire study period.

          -  Vaccination against influenza since January 2009 with a seasonal influenza vaccine.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the administration of the study vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of hypersensivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s).

          -  Acute clinically significant pulmonary, cardiovascular, hepatic, renal, neurological
             and psychiatric disorders, as determined by clinical evaluation or pre-existing
             laboratory screening tests.

          -  Acute disease and/or fever at the time of enrolment.

               -  Fever is defined as temperature &gt;=37.5°C on oral setting.

               -  Subjects with a minor illness without fever may be enrolled at the discretion of
                  the investigator.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the administration of the study vaccine or planned administration during the
             study.

          -  Any medical conditions in which IM injections are contraindicated

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gueglingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74363</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rudersberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wolmirstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>39326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freital</city>
        <state>Sachsen</state>
        <zip>01705</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3011 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <results_first_submitted>March 8, 2012</results_first_submitted>
  <results_first_submitted_qc>March 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2012</results_first_posted>
  <disposition_first_submitted>July 2, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 7, 2010</disposition_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccines</keyword>
  <keyword>GSK Bio's influenza vaccine GSK2186877A</keyword>
  <keyword>influenza infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113094</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="P3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="B3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="180"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="86"/>
            <count group_id="B4" value="370"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="5.18"/>
                    <measurement group_id="B2" value="74.8" spread="5.26"/>
                    <measurement group_id="B3" value="29.9" spread="6.55"/>
                    <measurement group_id="B4" value="64.2" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 ecchymosis, redness and swelling was ≥ 100 millimeter (mm) and grade 3 pain was considerable pain at rest, that prevented normal everyday activities.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
          <description>Grade 3 ecchymosis, redness and swelling was ≥ 100 millimeter (mm) and grade 3 pain was considerable pain at rest, that prevented normal everyday activities.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited Local AEs</title>
        <description>Duration was defined as number of days with any grade of local symptoms.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local AEs</title>
          <description>Duration was defined as number of days with any grade of local symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N=1; 0; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="NA">Information on duration of ecchymosis was missing from these subjects symptom sheets</measurement>
                    <measurement group_id="O3" value="NA">Information on duration of ecchymosis was missing from these subjects symptom sheets</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N=78; 12; 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N=21; 3; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N=22; 3; 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C-≤ 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade, grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
          <description>Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C-≤ 40.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade, grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gatrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gatrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gatrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited General AEs</title>
        <description>Duration was defined as number of days with any grade of general symptoms.</description>
        <time_frame>Day 0-6</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General AEs</title>
          <description>Duration was defined as number of days with any grade of general symptoms.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N=23; 3; 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N=53; 12; 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms (N=11; 5; 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N=31; 6; 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N=37; 7; 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N=20; 5; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N=7; 1; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-179</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit</title>
          <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting AEs of Specific Interest (AESI)</title>
        <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-179</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting AEs of Specific Interest (AESI)</title>
          <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AESI(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AESI(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AESI(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) up to Day 180</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Up to Day 180</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) up to Day 180</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) After Day 180</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>After Day 180</time_frame>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) After Day 180</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs) against separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 0 and Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Haemagglutination Inhibition (HI) Antibody Titers at Days 0 and 21</title>
          <description>Antibody titers were expressed as Geometric mean titers (GMTs) against separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" lower_limit="24.0" upper_limit="32.3"/>
                    <measurement group_id="O2" value="25.7" lower_limit="21.3" upper_limit="30.9"/>
                    <measurement group_id="O3" value="66.1" lower_limit="50.5" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="49.8" upper_limit="66.0"/>
                    <measurement group_id="O2" value="49.9" lower_limit="41.8" upper_limit="59.7"/>
                    <measurement group_id="O3" value="112.1" lower_limit="92.1" upper_limit="136.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" lower_limit="38.9" upper_limit="56.4"/>
                    <measurement group_id="O2" value="35.3" lower_limit="27.0" upper_limit="46.1"/>
                    <measurement group_id="O3" value="48.8" lower_limit="37.3" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.7" lower_limit="132.8" upper_limit="177.8"/>
                    <measurement group_id="O2" value="107.8" lower_limit="85.8" upper_limit="135.3"/>
                    <measurement group_id="O3" value="114.1" lower_limit="92.8" upper_limit="140.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" lower_limit="67.8" upper_limit="95.7"/>
                    <measurement group_id="O2" value="89.5" lower_limit="71.2" upper_limit="112.6"/>
                    <measurement group_id="O3" value="81.4" lower_limit="64.2" upper_limit="103.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.6" lower_limit="148.2" upper_limit="198.6"/>
                    <measurement group_id="O2" value="163.9" lower_limit="137.2" upper_limit="195.9"/>
                    <measurement group_id="O3" value="157.2" lower_limit="131.6" upper_limit="187.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Titers at Day 180</title>
        <description>Antibody titers were expressed as GMTs against separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Titers at Day 180</title>
          <description>Antibody titers were expressed as GMTs against separate vaccine strains. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" lower_limit="28.6" upper_limit="38.5"/>
                    <measurement group_id="O2" value="28.7" lower_limit="23.5" upper_limit="34.9"/>
                    <measurement group_id="O3" value="73.0" lower_limit="56.2" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" lower_limit="56.2" upper_limit="79.6"/>
                    <measurement group_id="O2" value="52.0" lower_limit="40.1" upper_limit="67.5"/>
                    <measurement group_id="O3" value="64.4" lower_limit="49.5" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="82.2" upper_limit="116.6"/>
                    <measurement group_id="O2" value="115.3" lower_limit="91.9" upper_limit="144.6"/>
                    <measurement group_id="O3" value="99.9" lower_limit="79.6" upper_limit="125.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seropositive to HI Antibodies at Days 0 and 21</title>
        <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.</description>
        <time_frame>Day 0 and Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seropositive to HI Antibodies at Days 0 and 21</title>
          <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seropositive to HI Antibodies at Day 180</title>
        <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seropositive to HI Antibodies at Day 180</title>
          <description>Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies at Day 21</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies at Day 21</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies at Day 180</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
        <time_frame>Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroconverted to HI Antibodies at Day 180</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors (SCF) at Day 21</title>
        <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
        <time_frame>At Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody Seroconversion Factors (SCF) at Day 21</title>
          <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.9" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.6" upper_limit="2.3"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.5" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.9" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.5" upper_limit="3.8"/>
                    <measurement group_id="O3" value="2.3" lower_limit="1.9" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.9" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.6" upper_limit="2.1"/>
                    <measurement group_id="O3" value="1.9" lower_limit="1.7" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody SCF at Day 180</title>
        <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>HI Antibody SCF at Day 180</title>
          <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
          <units>fold increase</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies at Days 0 and 21</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ to 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Day 0 and Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies at Days 0 and 21</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ to 1:40 that usually is accepted as indicating protection.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 21 for whom data concerning immunogenicity at day 21 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain at Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected to HI Antibodies at Day 180</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects Seroprotected to HI Antibodies at Day 180</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for humoral immunogenicity Day 180 for whom data concerning immunogenicity at day 180 were available.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strains Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21</title>
        <description>The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 0 and Day 21</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for cell mediated immunity (CMI) Day 21 in subjects for whom data concerning immunogenicity were available for at least one test, 21Days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean (GM) Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strains Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Days 0 and 21</title>
          <description>The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin 2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for cell mediated immunity (CMI) Day 21 in subjects for whom data concerning immunogenicity were available for at least one test, 21Days after vaccination.</population>
          <units>cells per million CD4+ T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [CD4-ALL DOUBLES] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505.28" spread="772.80"/>
                    <measurement group_id="O2" value="389.00" spread="856.40"/>
                    <measurement group_id="O3" value="770.48" spread="697.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-ALL DOUBLES] Day 21 (N=39;25;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706.88" spread="505.25"/>
                    <measurement group_id="O2" value="264.58" spread="781.85"/>
                    <measurement group_id="O3" value="1314.16" spread="747.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-ALL DOUBLES] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.14" spread="457.10"/>
                    <measurement group_id="O2" value="220.40" spread="539.54"/>
                    <measurement group_id="O3" value="423.12" spread="553.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-ALL DOUBLES] Day 21 (N=39;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.78" spread="391.17"/>
                    <measurement group_id="O2" value="181.29" spread="435.61"/>
                    <measurement group_id="O3" value="646.39" spread="529.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-ALL DOUBLES] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.12" spread="929.73"/>
                    <measurement group_id="O2" value="395.07" spread="401.74"/>
                    <measurement group_id="O3" value="1211.75" spread="589.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-ALL DOUBLES] Day 21 (N=38;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="833.66" spread="873.42"/>
                    <measurement group_id="O2" value="381.76" spread="708.30"/>
                    <measurement group_id="O3" value="1406.33" spread="663.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-CD40L] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496.13" spread="684.47"/>
                    <measurement group_id="O2" value="404.66" spread="688.08"/>
                    <measurement group_id="O3" value="641.91" spread="595.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-CD40L] Day 21 (N=39;25;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594.61" spread="444.86"/>
                    <measurement group_id="O2" value="222.79" spread="709.97"/>
                    <measurement group_id="O3" value="1156.09" spread="637.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-CD40L] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.19" spread="394.53"/>
                    <measurement group_id="O2" value="201.28" spread="331.40"/>
                    <measurement group_id="O3" value="349.47" spread="435.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-CD40L] Day 21 (N=39;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.03" spread="331.31"/>
                    <measurement group_id="O2" value="156.82" spread="359.54"/>
                    <measurement group_id="O3" value="508.67" spread="453.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-CD40L] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532.51" spread="808.78"/>
                    <measurement group_id="O2" value="351.89" spread="341.86"/>
                    <measurement group_id="O3" value="1036.33" spread="578.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-CD40L] Day 21 (N=38;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.53" spread="819.98"/>
                    <measurement group_id="O2" value="337.96" spread="600.56"/>
                    <measurement group_id="O3" value="1173.43" spread="534.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IFN-γ] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.48" spread="519.00"/>
                    <measurement group_id="O2" value="155.01" spread="472.80"/>
                    <measurement group_id="O3" value="507.94" spread="575.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IFN-γ] Day 21 (N=39;25;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.72" spread="397.50"/>
                    <measurement group_id="O2" value="148.60" spread="575.79"/>
                    <measurement group_id="O3" value="912.64" spread="564.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IFN-γ] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.87" spread="395.96"/>
                    <measurement group_id="O2" value="91.55" spread="351.37"/>
                    <measurement group_id="O3" value="245.90" spread="490.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IFN-γ] Day 21 (N=39;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.82" spread="293.17"/>
                    <measurement group_id="O2" value="85.83" spread="260.52"/>
                    <measurement group_id="O3" value="449.17" spread="407.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IFN-γ] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.91" spread="815.43"/>
                    <measurement group_id="O2" value="144.14" spread="286.54"/>
                    <measurement group_id="O3" value="850.80" spread="454.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IFN-γ] Day 21 (N=38;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.19" spread="746.60"/>
                    <measurement group_id="O2" value="185.93" spread="447.80"/>
                    <measurement group_id="O3" value="1059.08" spread="513.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IL2] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501.25" spread="632.36"/>
                    <measurement group_id="O2" value="336.49" spread="703.76"/>
                    <measurement group_id="O3" value="641.34" spread="620.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-IL2] Day 21 (N=39;25;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="603.99" spread="401.78"/>
                    <measurement group_id="O2" value="231.87" spread="687.91"/>
                    <measurement group_id="O3" value="1119.71" spread="663.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IL2] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.44" spread="364.77"/>
                    <measurement group_id="O2" value="159.48" spread="449.91"/>
                    <measurement group_id="O3" value="307.21" spread="428.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-IL2] Day 21 (N=39;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.89" spread="301.93"/>
                    <measurement group_id="O2" value="151.95" spread="362.38"/>
                    <measurement group_id="O3" value="507.44" spread="466.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IL2] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="511.34" spread="843.52"/>
                    <measurement group_id="O2" value="285.96" spread="363.09"/>
                    <measurement group_id="O3" value="980.90" spread="525.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-IL2] Day 21 (N=38;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686.04" spread="789.19"/>
                    <measurement group_id="O2" value="318.55" spread="631.64"/>
                    <measurement group_id="O3" value="1119.56" spread="621.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-TFN-α] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.67" spread="688.18"/>
                    <measurement group_id="O2" value="277.02" spread="793.58"/>
                    <measurement group_id="O3" value="689.52" spread="585.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [CD4-TFN-α] Day 21 (N=39;25;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.83" spread="447.33"/>
                    <measurement group_id="O2" value="279.39" spread="719.36"/>
                    <measurement group_id="O3" value="1083.09" spread="642.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-TFN-α] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.96" spread="407.82"/>
                    <measurement group_id="O2" value="176.04" spread="464.08"/>
                    <measurement group_id="O3" value="250.20" spread="480.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Uruguay [CD4-TFN-α ] Day 21(N=39;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350.86" spread="329.74"/>
                    <measurement group_id="O2" value="208.35" spread="392.20"/>
                    <measurement group_id="O3" value="575.88" spread="473.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-TFN-α] Day 0 (N=34;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.08" spread="843.99"/>
                    <measurement group_id="O2" value="324.83" spread="342.66"/>
                    <measurement group_id="O3" value="976.64" spread="580.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane [CD4-TFN-α] Day 21 (N=38;24;14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632.14" spread="767.97"/>
                    <measurement group_id="O2" value="367.95" spread="586.79"/>
                    <measurement group_id="O3" value="1126.10" spread="629.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The GM Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Day 180</title>
        <description>The markers assessed were CD40L, IL-2, TNF-α and IFN-γ and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 180</time_frame>
        <population>Analysis was performed on According-to-Protocol (ATP) cohort for cell mediated immunity (CMI) Day 180 in subjects for whom data concerning immunogenicity were available for at least one test, 180 Days after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The GM Number of Influenza Specific Cluster of Differentiation 4 (CD4) T-cells Per Million CD4 T-cells for Each Vaccine Strain Expressing at Least Two Different Markers or Expressing Different Combinations of Markers at Day 180</title>
          <description>The markers assessed were CD40L, IL-2, TNF-α and IFN-γ and vaccine strains tested included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
          <population>Analysis was performed on According-to-Protocol (ATP) cohort for cell mediated immunity (CMI) Day 180 in subjects for whom data concerning immunogenicity were available for at least one test, 180 Days after vaccination.</population>
          <units>cells per million CD4+ T-cells</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain A/Brisbane for CD4-ALL DOUBLES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.98" spread="507.43"/>
                    <measurement group_id="O2" value="395.98" spread="526.39"/>
                    <measurement group_id="O3" value="945.71" spread="669.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Uruguay for CD4-ALL DOUBLES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.28" spread="367.49"/>
                    <measurement group_id="O2" value="170.26" spread="295.26"/>
                    <measurement group_id="O3" value="523.37" spread="578.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B/Brisbane for CD4-ALL DOUBLES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.94" spread="885.94"/>
                    <measurement group_id="O2" value="514.93" spread="530.05"/>
                    <measurement group_id="O3" value="1156.78" spread="246.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Brisbane for CD4-CD40L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.87" spread="384.52"/>
                    <measurement group_id="O2" value="383.44" spread="485.65"/>
                    <measurement group_id="O3" value="838.17" spread="592.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Uruguay for CD4-CD40L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.10" spread="334.47"/>
                    <measurement group_id="O2" value="188.07" spread="251.35"/>
                    <measurement group_id="O3" value="444.32" spread="493.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B/Brisbane for CD4-CD40L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.67" spread="842.20"/>
                    <measurement group_id="O2" value="454.81" spread="488.31"/>
                    <measurement group_id="O3" value="1024.05" spread="242.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Brisbane for CD4-IFN-γ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.48" spread="457.12"/>
                    <measurement group_id="O2" value="195.30" spread="449.01"/>
                    <measurement group_id="O3" value="718.48" spread="530.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Uruguay for CD4-IFN-γ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.26" spread="326.33"/>
                    <measurement group_id="O2" value="93.12" spread="214.88"/>
                    <measurement group_id="O3" value="344.50" spread="475.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B/Brisbane for CD4-IFN-γ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.24" spread="775.13"/>
                    <measurement group_id="O2" value="191.20" spread="480.62"/>
                    <measurement group_id="O3" value="846.21" spread="187.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Brisbane for CD4-IL2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257.81" spread="343.17"/>
                    <measurement group_id="O2" value="337.02" spread="491.89"/>
                    <measurement group_id="O3" value="777.60" spread="606.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Uruguay for CD4-IL2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.94" spread="259.79"/>
                    <measurement group_id="O2" value="156.64" spread="247.58"/>
                    <measurement group_id="O3" value="364.47" spread="472.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B/Brisbane for CD4-IL2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378.41" spread="829.36"/>
                    <measurement group_id="O2" value="357.47" spread="487.00"/>
                    <measurement group_id="O3" value="940.07" spread="268.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Brisbane for CD4-TFN-α</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.89" spread="489.42"/>
                    <measurement group_id="O2" value="360.15" spread="499.75"/>
                    <measurement group_id="O3" value="833.70" spread="587.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain A/Uruguay for CD4-TFN-α</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.57" spread="332.69"/>
                    <measurement group_id="O2" value="211.11" spread="261.05"/>
                    <measurement group_id="O3" value="487.90" spread="502.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain B/Brisbane for CD4-TFN-α</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.41" spread="845.16"/>
                    <measurement group_id="O2" value="414.80" spread="454.02"/>
                    <measurement group_id="O3" value="953.49" spread="224.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed up to day 180 and after day 180. Systematically assessed frequent adverse events (AEs) and non-systematically assesed frequent AEs were assessed during 7 day and 21 day post vaccination period respectively.</time_frame>
      <desc>For the frequent adverse events, the number of participants at risk included those from Total Vaccinated Cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine</description>
        </group>
        <group group_id="E3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways diseas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vocal cord disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Pleural effusion was serious adverse event that occured after Day 180.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

